Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE AG10 is a novel, potent, and selective oral transthyretin (TTR) stabilizer being developed to treat TTR amyloidosis (ATTR). 31172685 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Assessment of myocardial uptake of Tc-99m-pyrophosphate (Tc-99m PYP) is pivotal in distinguishing transthyretin-associated cardiac amyloidosis (ATTR) from light chain amyloid (AL). 31172386 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. 31728713 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE The APOE genotype was determined in ATTR amyloidosis patients treated with Patisiran. 31648569 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. 31202744 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis, was discontinued after an imbalance in deaths in the "ENDEAVOUR" phase 3 clinical trial. 31821125 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) present with mutations in the transthyretin (TTR) gene that lead to the formation of amyloid deposits in peripheral nerves and heart. 31701435 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE ATTR amyloidosis is less recognized but is increasingly seen due to better recognition and improved diagnostic tools. 31706583 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE We, therefore, sequenced the TTR gene and used HRM in a group of 134 patients suspected of suffering from amyloidosis. 31740141 2020
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE The aim of the present study was to investigate if the type of amyloid fibril remains the same within ATTR Val30Met amyloidosis families. 30811423 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. 31445300 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Wild-type ATTR amyloidosis may be associated with unexpected death among the elderly. 31731233 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE The development of autonomic dysfunction impacts morbidity, disease progression, and mortality in patients with hereditary ATTR amyloidosis. 31473866 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Besides the well-known mechanisms of immune activation and inflammation in atherosclerosis causing ischemic cardiomyopathy or myocarditis, attention is focused on other mechanisms leading to heart failure such as transthyretin (TTR) amyloidosis or heart failure with preserved ejection fraction. 31083399 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease characterised by extracellular deposition of amyloid fibrils composed by transthyretin. 30683924 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE Only one patient in our study had light chain amyloidosis and showed higher TBR than patients with transthyretin amyloid: TBR 3.0 versus TBR median 1.44, IQR 1.33-1.69. 31140154 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE C-terminal TTR fragments are often present in amyloid-laden tissues of most patients with ATTR amyloidosis, and on the basis of <i>in vitro</i> studies, these fragments have been proposed to play important roles in amyloid formation. 31167790 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Clinicians should be more aware of the complex clinical profile of ATTR amyloidosis to avoid misdiagnosis in practice. 31718691 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis. 30470998 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Patients with hereditary ATTR amyloidosis occasionally show electrophysiological demyelinating features without conduction block following severe axonal degeneration. 30688105 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE At the same time, for one family of proteinopathies, the rare TTR amyloidoses, disease-modifying therapy has existed for almost 3 decades and two new types of disease-modifying therapy have become available more recently. 31699321 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE Proteins, well known from other amyloidoses like amyloid A (AA), prealbumin/transthyretin (PA), apolipoprotein A-I (ApoAI), and amyloid P component (APC), and also keratin were found with variable intensities in the cases. 31531279 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE ATTRm amyloidosis is due to variants in the TTR gene, with the substitution Val30Met as the most frequent mutation. 30295933 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 GeneticVariation disease BEFREE Tafamidis functions to delay the loss of function in transthyretin familial amyloid polyneuropathy (TTR-FAP), which is a rare inherited amyloidosis with progressive sensorimotor and autonomic polyneuropathy. 30618225 2019
Entrez Id: 7276
Gene Symbol: TTR
TTR
0.500 Biomarker disease BEFREE <b>Conclusion:</b> Tafamidis is an effective and safe oral medication for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. 31735059 2019